Relay Therapeutics, Inc. financial data

Symbol
RLAY on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
399 Binney Street, 2 Nd Floor, Cambridge, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 2, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.72 K % +9.21%
Debt-to-equity 15.2 % -5.89%
Return On Equity -42.7 % -19.4%
Return On Assets -37 % -20.4%
Operating Margin -1.03 K % +96.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 133 M shares +9.15%
Common Stock, Shares, Outstanding 132 M shares +8.91%
Entity Public Float 1.5 B USD -16.7%
Common Stock, Value, Issued 132 K USD +9.09%
Weighted Average Number of Shares Outstanding, Basic 131 M shares +7.85%
Weighted Average Number of Shares Outstanding, Diluted 112 M shares +18%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 35.3 M USD +2874%
Revenue from Contract with Customer, Excluding Assessed Tax 35.3 M USD +2874%
General and Administrative Expense 75.2 M USD +8.18%
Operating Income (Loss) -362 M USD -7.24%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -329 M USD -1.99%
Earnings Per Share, Basic -2.63 USD/shares +6.07%
Earnings Per Share, Diluted -2.63 USD/shares +6.07%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 153 M USD -5.21%
Accounts Receivable, after Allowance for Credit Loss, Current 211 K USD -12.4%
Other Assets, Current 7.3 M USD +78.8%
Assets, Current 770 M USD -19.6%
Property, Plant and Equipment, Net 9.88 M USD -17.4%
Operating Lease, Right-of-Use Asset 56.5 M USD -9.44%
Assets 841 M USD -18.9%
Accounts Payable, Current 7.97 M USD -32.6%
Accrued Liabilities, Current 22.4 M USD -20.3%
Contract with Customer, Liability, Current 83 K USD -80%
Liabilities, Current 37.1 M USD -47.3%
Operating Lease, Liability, Noncurrent 47.2 M USD -9.84%
Liabilities 95.7 M USD -37.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1.16 M USD +80%
Retained Earnings (Accumulated Deficit) -1.48 B USD -28.5%
Stockholders' Equity Attributable to Parent 746 M USD -15.6%
Liabilities and Equity 841 M USD -18.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -50.3 M USD +25%
Net Cash Provided by (Used in) Financing Activities 48.9 M USD +3672%
Net Cash Provided by (Used in) Investing Activities 10.5 M USD -86%
Common Stock, Shares Authorized 300 M shares 0%
Common Stock, Shares, Issued 132 M shares +8.91%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9.13 M USD -3.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 156 M USD -5.05%
Deferred Tax Assets, Valuation Allowance 300 M USD +30.1%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 312 M USD +25.8%
Depreciation 1.4 M USD +16.5%
Payments to Acquire Property, Plant, and Equipment 1.78 M USD -7.05%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -324 M USD -1.63%
Property, Plant and Equipment, Gross 34.5 M USD +14.9%
Operating Lease, Liability, Current 5.15 M USD +15.9%
Deferred Tax Assets, Operating Loss Carryforwards 141 M USD +18.2%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 2.23 B USD +9.15%
Deferred Tax Assets, Net of Valuation Allowance 12.3 M USD -30.3%
Share-based Payment Arrangement, Expense 91.7 M USD +42.8%